Global Gout Therapeutics Market
Global Gout Therapeutics Market

Gout Therapeutics Comprehensive Study by Type (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), Application (Hospitals, Clinics), Diseases Type (Acute Gout, Chronic Gout) Players and Region - Global Market Outlook to 2024

Gout Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 11.9%  

May 2019 Edition 228 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Gout is a form of arthritis which can be intensely painful and it is caused by having sodium urate crystals in joints. The approval of febuxostat, a non-purine-analogue inhibitor of xanthine oxidase, by the European Medicines Agency and the US Food and Drug Administration heralds a new era in the treatment of gout. Surging adoption of these biologics because of their ability to produce powerful anti-inflammatory action is likely to drive the market during the forecast period.According to AMA, the market for Gout Therapeutics is expected to register a CAGR of 11.9% during the forecast period to 2024. This growth is primarily driven by Increasing Adoption of Newer Therapies and Surging Number of Geriatric Population Across the World.

Globally, a noticeable market trend is evident Growing Focus on Regenerative Medicines by Key Players. Major Players, such as Regeneron Pharmaceuticals (United States), CymaBay Therapeutics (United States), LG Life Sciences (South Korea), Eisai Co., Ltd. (Japan), Antares Pharma (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Takeda Pharmaceuticals (Japan), GlaxoSmithKline (United Kingdom), Eli Lilly (United States), Merck & Co. (United States) and Novartis (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In December 2015, AstraZeneca’s product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the United States FDA to treat gout.

Market Drivers
  • Increasing Adoption of Newer Therapies
  • Surging Number of Geriatric Population Across the World

Market Trend
  • Growing Focus on Regenerative Medicines by Key Players

Restraints
  • Lack of Awareness in Developing Economies

Opportunities
Increased in Incidence and Prevalence of Gout in Developed Economies and Increasing Adoption of Biologics

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Urate-Lowering Agents
By Application
  • Hospitals
  • Clinics
By Diseases Type
  • Acute Gout
  • Chronic Gout

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Newer Therapies
      • 3.2.2. Surging Number of Geriatric Population Across the World
    • 3.3. Market Trends
      • 3.3.1. Growing Focus on Regenerative Medicines by Key Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gout Therapeutics, by Type, Application, Diseases Type and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Gout Therapeutics (Value)
      • 5.2.1. Global Gout Therapeutics by: Type (Value)
        • 5.2.1.1. NSAIDs
        • 5.2.1.2. Corticosteroids
        • 5.2.1.3. Colchicine
        • 5.2.1.4. Urate-Lowering Agents
      • 5.2.2. Global Gout Therapeutics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Gout Therapeutics by: Diseases Type (Value)
        • 5.2.3.1. Acute Gout
        • 5.2.3.2. Chronic Gout
      • 5.2.4. Global Gout Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Gout Therapeutics (Price)
      • 5.3.1. Global Gout Therapeutics by: Type (Price)
  • 6. Gout Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Regeneron Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CymaBay Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. LG Life Sciences (South Korea)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eisai Co., Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Antares Pharma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceuticals (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novartis (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Gout Therapeutics Sale, by Type, Application, Diseases Type and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Gout Therapeutics (Value)
      • 7.2.1. Global Gout Therapeutics by: Type (Value)
        • 7.2.1.1. NSAIDs
        • 7.2.1.2. Corticosteroids
        • 7.2.1.3. Colchicine
        • 7.2.1.4. Urate-Lowering Agents
      • 7.2.2. Global Gout Therapeutics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Gout Therapeutics by: Diseases Type (Value)
        • 7.2.3.1. Acute Gout
        • 7.2.3.2. Chronic Gout
      • 7.2.4. Global Gout Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Gout Therapeutics (Price)
      • 7.3.1. Global Gout Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gout Therapeutics: by Type(USD Billion)
  • Table 2. Gout Therapeutics NSAIDs , by Region USD Billion (2013-2018)
  • Table 3. Gout Therapeutics Corticosteroids , by Region USD Billion (2013-2018)
  • Table 4. Gout Therapeutics Colchicine , by Region USD Billion (2013-2018)
  • Table 5. Gout Therapeutics Urate-Lowering Agents , by Region USD Billion (2013-2018)
  • Table 6. Gout Therapeutics: by Application(USD Billion)
  • Table 7. Gout Therapeutics Hospitals , by Region USD Billion (2013-2018)
  • Table 8. Gout Therapeutics Clinics , by Region USD Billion (2013-2018)
  • Table 9. Gout Therapeutics: by Diseases Type(USD Billion)
  • Table 10. Gout Therapeutics Acute Gout , by Region USD Billion (2013-2018)
  • Table 11. Gout Therapeutics Chronic Gout , by Region USD Billion (2013-2018)
  • Table 12. South America Gout Therapeutics, by Country USD Billion (2013-2018)
  • Table 13. South America Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 14. South America Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 15. South America Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 16. Brazil Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 17. Brazil Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 18. Brazil Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 19. Argentina Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 20. Argentina Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 21. Argentina Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 22. Rest of South America Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 23. Rest of South America Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 24. Rest of South America Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 25. Asia Pacific Gout Therapeutics, by Country USD Billion (2013-2018)
  • Table 26. Asia Pacific Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 27. Asia Pacific Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 28. Asia Pacific Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 29. China Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 30. China Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 31. China Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 32. Japan Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 33. Japan Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 34. Japan Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 35. India Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 36. India Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 37. India Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 38. South Korea Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 39. South Korea Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 40. South Korea Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 41. Taiwan Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 42. Taiwan Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 43. Taiwan Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 44. Australia Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 45. Australia Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 46. Australia Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 47. Rest of Asia-Pacific Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 48. Rest of Asia-Pacific Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 49. Rest of Asia-Pacific Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 50. Europe Gout Therapeutics, by Country USD Billion (2013-2018)
  • Table 51. Europe Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 52. Europe Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 53. Europe Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 54. Germany Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 55. Germany Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 56. Germany Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 57. France Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 58. France Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 59. France Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 60. Italy Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 61. Italy Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 62. Italy Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 63. United Kingdom Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 64. United Kingdom Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 65. United Kingdom Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 66. Netherlands Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 67. Netherlands Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 68. Netherlands Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 69. Rest of Europe Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 70. Rest of Europe Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 71. Rest of Europe Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 72. MEA Gout Therapeutics, by Country USD Billion (2013-2018)
  • Table 73. MEA Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 74. MEA Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 75. MEA Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 76. Middle East Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 77. Middle East Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 78. Middle East Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 79. Africa Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 80. Africa Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 81. Africa Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 82. North America Gout Therapeutics, by Country USD Billion (2013-2018)
  • Table 83. North America Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 84. North America Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 85. North America Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 86. United States Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 87. United States Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 88. United States Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 89. Canada Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 90. Canada Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 91. Canada Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 92. Mexico Gout Therapeutics, by Type USD Billion (2013-2018)
  • Table 93. Mexico Gout Therapeutics, by Application USD Billion (2013-2018)
  • Table 94. Mexico Gout Therapeutics, by Diseases Type USD Billion (2013-2018)
  • Table 95. Gout Therapeutics: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Gout Therapeutics: by Type(USD Billion)
  • Table 109. Gout Therapeutics NSAIDs , by Region USD Billion (2019-2024)
  • Table 110. Gout Therapeutics Corticosteroids , by Region USD Billion (2019-2024)
  • Table 111. Gout Therapeutics Colchicine , by Region USD Billion (2019-2024)
  • Table 112. Gout Therapeutics Urate-Lowering Agents , by Region USD Billion (2019-2024)
  • Table 113. Gout Therapeutics: by Application(USD Billion)
  • Table 114. Gout Therapeutics Hospitals , by Region USD Billion (2019-2024)
  • Table 115. Gout Therapeutics Clinics , by Region USD Billion (2019-2024)
  • Table 116. Gout Therapeutics: by Diseases Type(USD Billion)
  • Table 117. Gout Therapeutics Acute Gout , by Region USD Billion (2019-2024)
  • Table 118. Gout Therapeutics Chronic Gout , by Region USD Billion (2019-2024)
  • Table 119. South America Gout Therapeutics, by Country USD Billion (2019-2024)
  • Table 120. South America Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 121. South America Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 122. South America Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 123. Brazil Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 124. Brazil Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 125. Brazil Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 126. Argentina Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 127. Argentina Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 128. Argentina Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 129. Rest of South America Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 130. Rest of South America Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 131. Rest of South America Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 132. Asia Pacific Gout Therapeutics, by Country USD Billion (2019-2024)
  • Table 133. Asia Pacific Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 134. Asia Pacific Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 135. Asia Pacific Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 136. China Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 137. China Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 138. China Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 139. Japan Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 140. Japan Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 141. Japan Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 142. India Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 143. India Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 144. India Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 145. South Korea Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 146. South Korea Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 147. South Korea Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 148. Taiwan Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 149. Taiwan Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 150. Taiwan Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 151. Australia Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 152. Australia Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 153. Australia Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 154. Rest of Asia-Pacific Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 155. Rest of Asia-Pacific Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 156. Rest of Asia-Pacific Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 157. Europe Gout Therapeutics, by Country USD Billion (2019-2024)
  • Table 158. Europe Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 159. Europe Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 160. Europe Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 161. Germany Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 162. Germany Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 163. Germany Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 164. France Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 165. France Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 166. France Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 167. Italy Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 168. Italy Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 169. Italy Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 170. United Kingdom Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 171. United Kingdom Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 172. United Kingdom Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 173. Netherlands Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 174. Netherlands Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 175. Netherlands Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 176. Rest of Europe Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 177. Rest of Europe Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 178. Rest of Europe Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 179. MEA Gout Therapeutics, by Country USD Billion (2019-2024)
  • Table 180. MEA Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 181. MEA Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 182. MEA Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 183. Middle East Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 184. Middle East Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 185. Middle East Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 186. Africa Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 187. Africa Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 188. Africa Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 189. North America Gout Therapeutics, by Country USD Billion (2019-2024)
  • Table 190. North America Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 191. North America Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 192. North America Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 193. United States Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 194. United States Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 195. United States Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 196. Canada Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 197. Canada Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 198. Canada Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 199. Mexico Gout Therapeutics, by Type USD Billion (2019-2024)
  • Table 200. Mexico Gout Therapeutics, by Application USD Billion (2019-2024)
  • Table 201. Mexico Gout Therapeutics, by Diseases Type USD Billion (2019-2024)
  • Table 202. Gout Therapeutics: by Type(USD/Units)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gout Therapeutics: by Type USD Billion (2013-2018)
  • Figure 5. Global Gout Therapeutics: by Application USD Billion (2013-2018)
  • Figure 6. Global Gout Therapeutics: by Diseases Type USD Billion (2013-2018)
  • Figure 7. South America Gout Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Gout Therapeutics Share (%), by Country
  • Figure 9. Europe Gout Therapeutics Share (%), by Country
  • Figure 10. MEA Gout Therapeutics Share (%), by Country
  • Figure 11. North America Gout Therapeutics Share (%), by Country
  • Figure 12. Global Gout Therapeutics: by Type USD/Units (2013-2018)
  • Figure 13. Global Gout Therapeutics share by Players 2018 (%)
  • Figure 14. Global Gout Therapeutics share by Players (Top 3) 2018(%)
  • Figure 15. Global Gout Therapeutics share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 19. CymaBay Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 20. CymaBay Therapeutics (United States) Revenue: by Geography 2018
  • Figure 21. LG Life Sciences (South Korea) Revenue, Net Income and Gross profit
  • Figure 22. LG Life Sciences (South Korea) Revenue: by Geography 2018
  • Figure 23. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Eisai Co., Ltd. (Japan) Revenue: by Geography 2018
  • Figure 25. Antares Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 26. Antares Pharma (United States) Revenue: by Geography 2018
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2018
  • Figure 29. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 31. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2018
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 35. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly (United States) Revenue: by Geography 2018
  • Figure 37. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co. (United States) Revenue: by Geography 2018
  • Figure 39. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 41. Global Gout Therapeutics: by Type USD Billion (2019-2024)
  • Figure 42. Global Gout Therapeutics: by Application USD Billion (2019-2024)
  • Figure 43. Global Gout Therapeutics: by Diseases Type USD Billion (2019-2024)
  • Figure 44. South America Gout Therapeutics Share (%), by Country
  • Figure 45. Asia Pacific Gout Therapeutics Share (%), by Country
  • Figure 46. Europe Gout Therapeutics Share (%), by Country
  • Figure 47. MEA Gout Therapeutics Share (%), by Country
  • Figure 48. North America Gout Therapeutics Share (%), by Country
  • Figure 49. Global Gout Therapeutics: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Regeneron Pharmaceuticals (United States)
  • CymaBay Therapeutics (United States)
  • LG Life Sciences (South Korea)
  • Eisai Co., Ltd. (Japan)
  • Antares Pharma (United States)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca (United Kingdom)
  • Takeda Pharmaceuticals (Japan)
  • GlaxoSmithKline (United Kingdom)
  • Eli Lilly (United States)
  • Merck & Co. (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Teijin Pharma (Japan) , JW Pharmaceutical (South Korea) , Vertex Pharmaceuticals (United States) , Astellas Pharma (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation